Skip to main content
SpringerLink
Log in

Lipid Nephrotoxicity: New Concept for an Old Disease

  • Hypertension and Metabolic Disarray: Diabetes Mellitus, Insulin Resistance, and Obesity (E Reisin, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The prevalence of obesity in the United States remains high, exceeding 30% in most states. As this trend continues unhindered, we will continue see a persistent rise in obesity-related metabolic effects—hypertension, dyslipidemia, diabetes mellitus, and atherosclerosis. These diseases are also the leading causes of chronic kidney diseases and end-stage renal disease. The lipid nephrotoxicity hypothesis, proposed over three decades ago, suggested that proteinuria, decreased albumin levels, and the resultant hyperlipidemia may cause a glomerulosclerosis similar to atherosclerosis. More recent studies have demonstrated the role of oxidized high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles in the progression of kidney disease. Elucidation of the role of lipid-lowering therapies and the concomitant improvement in tubulointerstitial and glomerular diseases is a further evidence of the role of lipids in renal injury. Synergistic effects of lipid-lowering drugs and blockers of the renin-angiotensin-aldosterone system (RAAS) in renal protection have also been documented. Dyslipidemia in renal disease is usually characterized by elevated LDL cholesterol, low HDL cholesterol, and high triglycerides. After an initial glomerular injury, likely to be inflammatory, a series of self-perpetuating events occur. Increased glomerular basement permeability leads to loss of lipoprotein lipase activators, which results in hyperlipidemia. Circulating LDL has a charge affinity for glycoaminoglycans in the glomerular basement membrane and further increases its permeability. Substantial amounts of filtered lipoprotein cause proliferation of mesangial cells. Proximal tubules reabsorb some of the filtered lipoprotein, and the remainder is altered during passage through the nephron. If intraluminal pH is close to the isoelectric point of the apoprotein, luminal apoprotein will precipitate, causing tubulointerstitial disease. This review shows the evidence for the role of lipids in development of chronic renal disease, the pathophysiology of lipid nephrotoxicity, and strategies available to clinicians to slow the progression of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as • Of importance •• Of major importance

  1. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney diease. Clin J Am Soc Nephrol. 2007;2:550–62.

    Article  PubMed  CAS  Google Scholar 

  2. • Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5:713–21. This article describes the understanding of the pathogenesis of lipid-mediated renal and vascular injury and the role of lipid-lowering treatment in affected patients.

    Article  PubMed  CAS  Google Scholar 

  3. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363–79.

    Article  PubMed  CAS  Google Scholar 

  4. •• Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of highdensity lipoprotein in chronic kidney disease. Transl Res. 2009;153:77–85. This article describes the alteration of the composition and antioxidant activity of HDL in CKD, which contributes to a heightened risk of atherosclerosis in affected patients.

    Article  PubMed  CAS  Google Scholar 

  5. Liu Y, Coresh J, Eustance J, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–9.

    Article  PubMed  CAS  Google Scholar 

  6. Cases A, Elisabeth C. Dyslipidemia and the progression of renal disease in chronic renal failure. Kidney Int. 2005;68:87–93.

    Article  Google Scholar 

  7. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int. 1981;19:625–37.

    Article  PubMed  CAS  Google Scholar 

  8. Moorhead JF, Chan MK, el-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitialdisease. Lancet. 1982;2:1309–11.

    Article  PubMed  CAS  Google Scholar 

  9. Mahley RW. Atherogenic hyperlipoproteinemia. Med Clin North Am. 1982;66:75–402.

    Google Scholar 

  10. Lee HS, Jeong JY, Kim BC. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int. 1997;51:1151–9.

    Article  PubMed  CAS  Google Scholar 

  11. Misra RP, Berman LB. Studies in glomerular basement membrane II isolation and characterization of disease glomerular basement membrane. Lab Invest. 1965;18:1–35.

    Google Scholar 

  12. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis. 2000;36:272–81.

    Article  PubMed  CAS  Google Scholar 

  13. Fox CS, Larson MG, Leip EP, Culleton B. Predictors of new onset kidney disease in a community-based population. JAMA. 2004;291:844–50.

    Article  PubMed  CAS  Google Scholar 

  14. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities. Kidney Int. 2000;58:293–301.

    Article  PubMed  CAS  Google Scholar 

  15. Manttari M, Tiula E, Alikoski T, et al. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26:670–5.

    PubMed  CAS  Google Scholar 

  16. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–91.

    PubMed  CAS  Google Scholar 

  17. Gall MA, Hougaard P, Borch-Johnsen K, et al. Risk factors for development of incipient and overt diabetic nephropathy in participants with non-insulin dependent diabetes mellitus: prospective observational study. Br Med J. 1997;314:783–8.

    Article  CAS  Google Scholar 

  18. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998–1004.

    Article  PubMed  CAS  Google Scholar 

  19. • Reisin E, Liao J, Ebenezer P, et al. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese Zucker rats fed with an atherogenic diet. Am Med Sci. 2009;338(4):301–9. This article describes the protective effect of statins on the development of glomerular hypertrophy and inflammation in obese rats.

    Article  Google Scholar 

  20. Tonelli M, Moye L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605–13.

    Article  PubMed  CAS  Google Scholar 

  21. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260–9.

    Article  PubMed  CAS  Google Scholar 

  22. Athyros VG, Papageorgiou AA, Elisaf M, et al. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin. 2003;19:615–7.

    Article  PubMed  CAS  Google Scholar 

  23. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.

    Article  PubMed  Google Scholar 

  24. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–70.

    Article  PubMed  CAS  Google Scholar 

  25. Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102:52–60.

    Article  PubMed  CAS  Google Scholar 

  26. Massy ZA, Kim Y, Guijarro C, et al. Low-density lipoproteininduced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536–40.

    Article  PubMed  CAS  Google Scholar 

  27. Chmielewski M, Bryl E, Marzec L, et al. Expression of scavenger receptor CD36 in chronic renal failure patients. Artif Organs. 2005;29:608–14.

    Article  PubMed  CAS  Google Scholar 

  28. Zelvyte I, Dominaitiene R, Crisby M, et al. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002;45:147–54.

    Article  PubMed  CAS  Google Scholar 

  29. Vamvakopoulos JE, Green C. HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection. BMC Cardiovasc Disord. 2003;3:6.

    Article  PubMed  Google Scholar 

  30. Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol. 2004;15:1616–22.

    Article  PubMed  Google Scholar 

  31. Bussolati B, DeregibuS MC, Fonsato V, et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating phosphatidylinositol 3-kinase/AKT-signalling pathway. J Am Soc Nephrol. 2005;16:1936–47.

    Article  PubMed  CAS  Google Scholar 

  32. O’Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med. 2006;144:625–33.

    PubMed  Google Scholar 

  33. Thakur V, Morse S, Reisin E. Functional and structural renal changes in the early stages of obesity. Contrib Nephrol. 2006;151:135–50.

    Article  PubMed  Google Scholar 

  34. • Liao J, Soltani Z, Ebenezer P, et al. Tesaglitazar, a dual peroxisome proliferator activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats. Nephron Exp Nephrol. 2010;114:55–62. This article describes the effect of PPAR alpha/gamma in improving metabolic syndrome, kidney injury, and the lipid panel in obese Zucker rats.

    Article  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Nephrology and Hypertension Division, LSUHSC NO, 1542 Tulane Avenue, New Orleans, LA, 70112, USA

    Leonard Gyebi, Zohreh Soltani & Efrain Reisin

Authors
  1. Leonard Gyebi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zohreh Soltani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Efrain Reisin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zohreh Soltani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gyebi, L., Soltani, Z. & Reisin, E. Lipid Nephrotoxicity: New Concept for an Old Disease. Curr Hypertens Rep 14, 177–181 (2012). https://doi.org/10.1007/s11906-012-0250-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-012-0250-2

Keywords

Search

Navigation